Antibodies: Timeline of key events

Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.

The drug is enfortumab vedotin-ejfv, an antibody drug conjugate. It was given accelerated approval for adult patients with locally advanced or metastatic urothelial cancer who failed to respond to PD1 immune checkpoint therapy or platinum-containing chemotherapy. 2019-12-18T00:00:00+00002019-12-23T00:00:00+0000
Date Event People Places Sciences
18 Dec 2019FDA granted accelerated approval for Seattle Genetics drug for advanced urothelial cancer Seattle GeneticsMonoclonal antibodies, Oncology
23 Dec 2019Seattle Genetics submitted New Drug Application to FDA for testing tucatinib in patients with locally advanced or metatastic HER2-positive breast cancer Seattle GeneticsMonoclonal antibodies, Oncology

18 Dec 2019

FDA granted accelerated approval for Seattle Genetics drug for advanced urothelial cancer

23 Dec 2019

Seattle Genetics submitted New Drug Application to FDA for testing tucatinib in patients with locally advanced or metatastic HER2-positive breast cancer

Respond to or comment on this page on our feeds on Facebook, Instagram or Twitter.